Calcium blockers decrease the bortezomib resistance in mantle cell lymphoma via manipulation of tissue transglutaminase activities

Blood

Volumn 119, Issue 11, 2012, Pages 2568-2578

  Jung, Hyun Joo ^a,b   Chen, Zheng ^a   Wang, Michael ^c   Fayad, Luis ^c   Romaguera, Jorge ^c   Kwak, Larry W ^c   McCarty, Nami ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^b Ajou University Medical Center   (South Korea)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; CALCIMYCIN; CALCIUM CHANNEL BLOCKING AGENT; CALCIUM IONOPHORE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PERILLYL ALCOHOL; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL; CANCER SURVIVAL; CONTROLLED STUDY; DOWN REGULATION; DRUG POTENTIATION; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME MODIFICATION; GENE EXPRESSION; GENE TARGETING; HUMAN; HUMAN TISSUE; MANTLE CELL LYMPHOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN CROSS LINKING; SIGNAL TRANSDUCTION;

EID: 84863374462     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-09-377598     Document Type: Article

References (49)

1. Romaguera JE, Fayad LE, Feng L, et al. Tenyear follow-up after intense chemoimmunotherapy with Rituximab-HyperCVAD alternating with Rituximab-high dose methotrexate/cytarabine (R-MA) and without stem cell transplantation in patients with untreated aggressive mantle cell lymphoma. Br J Haematol. 2010;150(2):200-208.
2. Goy A, Kahl B. Mantle cell lymphoma: The promise of new treatment options. Crit Rev Oncol Hematol. 2011;80(1):69-86.
3. Romaguera JE, Fayad LE, McLaughlin P, et al. Phase I trial of bortezomib in combination with rituximab-HyperCVAD alternating with rituximab, methotrexate and cytarabine for untreated aggressive mantle cell lymphoma. Br J Haematol. 2010;151(1):47-53.
4. Campo E, Raffeld M, Jaffe ES. Mantle-cell lymphoma. Semin Hematol. 1999;36(2):115-127. (Pubitemid 29214065)
5. Mounter PJ, Lennard AL. Management of non- Hodgkin's lymphomas. Postgrad Med J. 1999;75(879):2-6.
6. Salaverria I, Perez-Galan P, Colomer D, Campo E. Mantle cell lymphoma: from pathology and molecular pathogenesis to new therapeutic perspectives. Haematologica. 2006;91(1):11-16. (Pubitemid 43235380)
7. Pileri SA, Falini B. Mantle cell lymphoma. Haematologica. 2009;94(11):1488-1492.
8. Kane RC, Dagher R, Farrell A, et al. Bortezomib for the treatment of mantle cell lymphoma. Clin Cancer Res. 2007;13(18 Pt 1):5291-5294. (Pubitemid 47510352)
9. Rajkumar SV, Richardson PG, Hideshima T, Anderson KC. Proteasome inhibition as a novel therapeutic target in human cancer. J Clin Oncol. 2005;23(3):630-639. (Pubitemid 46224241)
10. Voorhees PM, Dees EC, O'Neil B, Orlowski RZ. The proteasome as a target for cancer therapy. Clin Cancer Res. 2003;9(17):6316-6325. (Pubitemid 38031815)
11. Adams J. The proteasome: a suitable antineoplastic target. Nat Rev Cancer. 2004;4(5):349-360. (Pubitemid 38579481)
12. Pham LV, Tamayo AT, Yoshimura LC, Lo P, Ford RJ. Inhibition of constitutive NF-kappa B activation in mantle cell lymphoma B cells leads to induction of cell cycle arrest and apoptosis. J Immunol. 2003;171(1):88-95. (Pubitemid 36745276)
13. Yang DT, Young KH, Kahl BS, Markovina S, Miyamoto S. Prevalence of bortezomib-resistant constitutive NF-kappaB activity in mantle cell lymphoma. Mol Cancer. 2008;7:40.
14. O'Connor OA, Wright J, Moskowitz C, et al. Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma. J Clin Oncol. 2005;23(4):676-684. (Pubitemid 46237441)
15. Goy A, Younes A, McLaughlin P, et al. Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma. J Clin Oncol. 2005;23(4):667-675. (Pubitemid 46224166)
16. Fribley A, Zeng Q, Wang C.-Y. Proteasome inhibitor PS341 induces apoptosis through induction of endoplasmic reticulum stress-reactive oxygen species in head and neck squamous cell carcinoma cells. Mol Cell Biol. 2004;24(22):9695-9704. (Pubitemid 39458799)
17. Obeng EA, Carlson LM,Gutman DM, HarringtonWJ, Lee KP, Boise LH. Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells. Blood. 2006;107(12):4907-4916. (Pubitemid 43882644)
18. Weniger MA, Rizzatti EG, Perez-Galan P, et al. Treatment-induced oxidative stress and cellular antioxidant capacity determine response to bortezomib in mantle cell lymphoma. Clin Cancer Res. 2011;17(15):5101-5112.
19. Ri M, Iida S, Nakashima T, et al. Bortezomib-resistant myeloma cell lines: a role for mutated PSMB5 in preventing the accumulation of unfolded proteins and fatal ER stress. Leukemia. 2010;24(8):1506-1512.
20. Hideshima T, Ikeda H, Chauhan D, Okawa Y, Raje N, et al. Bortezomib induces canonical nuclear factor-kappaB activation in multiple myeloma cells. Blood. 2009;114(5):1046-1052.
21. Dolcet X, Llobet D, Encinas M et al. Proteasome inhibitors induce death but activate NF-kappaB on endometrial carcinoma cell lines and primary culture explants. J Biol Chem. 2006;281(31):22118-22130. (Pubitemid 44181916)
22. Chen Z, Ayala P, Wang M, et al. Prospective isolation of clonogenic mantle cell lymphoma-initiating cells. Stem Cell Res. 2010;5(3):212-225.
23. Jung HJ, Chen Z, McCarty N. Stem-like tumor cells confer drug resistant properties to mantle cell lymphoma. Leuk Lymphoma. 2011;52(6): 1066-79.
24. Jung HJ, Chen Z, Fayad L, et al. Bortezomib-resistant nuclear factor kappa B expression in stem like cells in mantle cell lymphoma (MCL). Exp Hematol. 2012;40(2):107-118.
25. Yeruva L, Hall C, Elegbede JA, Carper SW. Perillyl alcohol and methyl jasmonate sensitize cancer cells to cisplatin. Anticancer Drugs. 2010;21(1):1-9.
26. Berchtold CM, Chen KS, Miyamoto S, Gould MN. Perillyl alcohol inhibits a calcium-dependent constitutive nuclear factor-kappaB pathway. Cancer Res. 2005;65(18):8558-8566. (Pubitemid 41330625)
27. Meister S, Frey B, Lang VR, et al. Calcium channel blocker verapamil enhances endoplasmic reticulum stress and cell death induced by proteasome inhibition in myeloma cells. Neoplasia. 2010;12(7):550-561.
28. Griffin M, Casadio R, Bergamini CM. Transglutaminases: nature's biological glues. Biochem J. 2002;368(pt 2):377-396. (Pubitemid 35454517)
29. Boehm JE, Singh U, Combs C, Antonyak MA, Cerione RA. Tissue transglutaminase protects against apoptosis by modifying the tumor suppressor protein p110 Rb. J Biol Chem. 2002;277(23):20127-20130. (Pubitemid 34967301)
30. Mehta K, Fok J, Miller FR, Koul D, Sahin AA. Prognostic significance of tissue transglutaminase in drug resistant and metastatic breast cancer. Clin Cancer Res. 2004;10(23):8068-76. (Pubitemid 39587548)
31. Akimov SS, Belkin AM. Cell-surface transglutaminase promotes fibronectin assembly via interaction with the gelatin-binding domain of fibronectin: a role in TGFbeta-dependent matrix deposition. J Cell Sci. 2001;114(Pt 16):2989-3000. (Pubitemid 32821537)
32. Yamaguchi H, Wang HG. Tissue transglutaminase serves as an inhibitor of apoptosis by crosslinking caspase 3 in thapsigargin-treated cells. Mol Cell Biol. 2006;26(2):569-579. (Pubitemid 43089769)
33. Kim DS, Park SS, Nam BH, Kim IH, Kim SY. Reversal of drug resistance in breast cancer cells by transglutaminase 2 inhibition and nuclear factorkappaB inactivation. Cancer Res. 2006;66(22):10936-10943.
34. Mehta K. High levels of transglutaminase expression in doxorubicin-resistant human breast carcinoma cells. Int J Cancer. 1994;58(3):400-406. (Pubitemid 24254651)
35. Mann AP, Verma A, Sethi G, et al. Overexpression of tissue transglutaminase leads to constitutive activation of nuclear factor-kappaB in cancer cells: delineation of a novel pathway. Cancer Res. 2006;66(17):8788-8795. (Pubitemid 44449196)
36. Yuan L, Choi K, Khosla C, et al. Tissue transglutaminase 2 inhibition promotes cell death and chemosensitivity in glioblastomas. Mol Cancer Ther. 2005;4(9):1293-1302.
37. Verma A, Mehta K. Transglutaminase-mediated activation of nuclear transcription factor-kappaB in cancer cells: a new therapeutic opportunity. Curr Cancer Drug Targets. 2007;7(6):559-565. (Pubitemid 47358142)
38. Lee J, Kim YS, Choi DH, et al. Transglutaminase 2 induces nuclear factor-kappaB activation via a novel pathway in BV-2 microglia. J Biol Chem. 2004;279(51):53725-53735. (Pubitemid 40051881)
39. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul. 1984;22:27-55.
40. Chou TC, Talalay P. Generalized equations for the analysis of inhibitions of Michaelis-Menten and higher-order kinetic systems with two or more mutually exclusive and nonexclusive inhibitors. Eur J Biochem. 1981;115(1):207-216.
41. Chou TC. Derivation and properties of Michaelis- Menten type and Hill type equations for reference ligands. J Theor Biol. 1976;59(2):253-276.
42. Baumeister W, Walz J, Zuhl F, Seemuller E. The proteasome: paradigm of a self-compartmentalizing protease. Cell. 1998;92(3):367-380. (Pubitemid 28093014)
43. Coux O, Tanaka K, Goldberg AL. Structure and functions of the 20S and 26S proteasomes. Annu Rev Biochem. 1996;65:801-847. (Pubitemid 26255262)
44. Kim SY. Transglutaminase 2 in inflammation. Front Biosci. 2006;11:3026-3035.
45. Ientile R, Caccamo D, Griffin M. Tissue transglutaminase and the stress response. Amino Acids. 2007;33(2):385-394. (Pubitemid 47222963)
46. Stratton SP, Alberts DS, Einspahr JG, et al. A phase 2a study of topical perillyl alcohol cream for chemoprevention of skin cancer. Cancer Prev Res (Phila). 2010;3(2):160-169.
47. da Fonseca CO, Simao M, Lins IR, Caetano RO, Futuro D, Quirico-Santos T. Efficacy of monoterpene perillyl alcohol upon survival rate of patients with recurrent glioblastoma. J Cancer Res Clin Oncol. 2011;137(2):287-293.
48. Elsässer HP, MacDonald R, Dienst M, Kern HF. Characterization of a transglutaminase expressed in human pancreatic adenocarcinoma cells. Eur J Cell Biol. 1993;61(2):321-328. (Pubitemid 23307544)
49. Verma A, Mehta K. Tissue transglutaminase-mediated chemoresistance in cancer cells. Drug Resist Updat. 2007;10(4-5):144-151. (Pubitemid 47446401)